Advocacy & Practice Updates — Advocacy & Practice
JZ Modifier Deadline is Right Around the Corner: ASRS has Resources to Help Get You Started
Beginning July 1, all claims for single-dose Part B drugs administered to original Medicare patients must include a JW modifier to indicate unused volume of drug or a new JZ modifier to indicate the entire volume of the drug was used.
This policy was included in the 2023 Medicare physician fee schedule final rule as CMS began implementation of a new law that requires manufacturers to rebate Medicare for un-sued, discarded volume of Part B drugs. Additional information on the policy is available on the ASRS website.
ASRS and others in the medical community successfully advocated that CMS delay the implementation of the new JZ modifier and provide additional guidance. ASRS continues to advocate that CMS exempt all ophthalmic drugs, or those with volumes of 1mL or less to ensure manufacturers do not reduce the volume in single-use vials or pre-filled syringes and thereby lead to underdosing.
If you have questions, please contact Allison Madson, vice president of health policy.
(Published May 31, 2023)